Biomea Fusion, Inc. (BMEA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biomea Fusion, Inc. (BMEA) trades at $1.39 with AI Score 26/100 (Grade F). Biomea Fusion, Inc. is a biopharmaceutical company focused on discovering and developing covalent small molecule drugs for genetically defined cancers and metabolic diseases. Market cap: $82.40M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for BMEA: BMEA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMEA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BMEA: 1/1 perspectives are bearish.
How is this calculated? →Biomea Fusion, Inc. (BMEA) Healthcare & Pipeline Overview
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of covalent small molecule drugs, with a focus on treating genetically defined cancers and metabolic diseases. Their lead candidate, BMF-219, targets menin, a key regulator in oncogenic signaling, positioning them in the competitive biotechnology landscape.
What Is the Investment Thesis for BMEA?
Biomea Fusion, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its innovative approach to covalent drug discovery and the clinical progress of its lead candidate, BMF-219. The company's focus on genetically defined cancers and metabolic diseases allows for targeted drug development and potential for higher success rates in clinical trials. A key value driver is the continued advancement of BMF-219 through clinical trials, with positive data readouts serving as significant catalysts for stock appreciation. The company's current market capitalization of $82.40M reflects the inherent risks associated with early-stage drug development, including potential clinical trial failures and regulatory hurdles. Successful commercialization of BMF-219 or other pipeline candidates could lead to substantial revenue growth and increased shareholder value. The company's beta of -0.27 suggests a low correlation with overall market movements, potentially offering some downside protection in volatile market conditions.
Based on FMP financials and quantitative analysis
BMEA Key Highlights
- Biomea Fusion's lead product candidate, BMF-219, is an orally bioavailable covalent inhibitor of menin, targeting oncogenic signaling in multiple cancers.
- The company was founded in 2017, indicating it is still in an early stage of development with potential for high growth.
- Biomea Fusion is focused on developing covalent small molecule drugs, a differentiated approach that could lead to more effective and durable therapies.
- The company's headquarters are located in Redwood City, California, a hub for biotechnology innovation.
- Biomea Fusion has a market capitalization of $82.40M, reflecting its position as a smaller player in the biotechnology industry.
Who Are BMEA's Competitors?
BMEA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMEA's Key Strengths?
- Innovative covalent drug discovery platform.
- Lead product candidate targeting a validated oncogenic pathway.
- Experienced management team.
- Focus on genetically defined diseases.
What Are BMEA's Weaknesses?
- Early-stage clinical development with high risk of failure.
- Limited financial resources.
- Dependence on a single lead product candidate.
- Limited commercial infrastructure.
What Could Drive BMEA Stock Higher?
- Data readouts from ongoing clinical trials of BMF-219 in genetically defined cancers.
- Initiation of new clinical trials for BMF-219 in additional indications.
- Progress in expanding the company's pipeline with new covalent drug candidates.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for BMEA?
- Financial-distress signal — its Altman Z-Score of -14.50 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for BMF-219 or other drug candidates.
- Regulatory hurdles in obtaining approvals for new therapies.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Changes in the healthcare landscape and reimbursement policies.
- Dependence on successful development and commercialization of BMF-219.
What Are the Growth Opportunities for BMEA?
- Advancement of BMF-219 in Clinical Trials: The primary growth opportunity lies in the successful advancement of BMF-219 through ongoing and planned clinical trials. Positive data readouts from these trials, particularly in Phase 2 and Phase 3 studies, could significantly increase the company's valuation and attract partnerships. The market for targeted cancer therapies is substantial, with the global oncology market projected to reach hundreds of billions of dollars by 2030. Success in this area would establish Biomea Fusion as a key player in the oncology space.
- Expansion of Pipeline with New Covalent Drugs: Biomea Fusion has the opportunity to expand its pipeline by developing additional covalent small molecule drugs targeting other genetically defined diseases. This would diversify the company's risk profile and create multiple avenues for growth. The market for novel therapeutics is constantly evolving, with a growing demand for personalized medicine approaches. By leveraging its expertise in covalent drug discovery, Biomea Fusion can capitalize on this trend.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Biomea Fusion with access to additional funding, expertise, and resources. These collaborations could accelerate the development and commercialization of its drug candidates. The biotechnology industry is characterized by frequent collaborations, as companies seek to leverage each other's strengths and share the risks associated with drug development.
- Expansion into Metabolic Diseases: Biomea Fusion's focus on both genetically defined cancers and metabolic diseases presents a dual growth opportunity. The metabolic disease market, including diabetes and obesity, is a large and growing market with significant unmet medical needs. Developing covalent drugs for these conditions could provide a substantial revenue stream for the company. The increasing prevalence of metabolic diseases worldwide is driving demand for innovative treatments.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is crucial for commercializing Biomea Fusion's drug candidates. Successful regulatory approvals would allow the company to market and sell its products, generating revenue and establishing its presence in the pharmaceutical market. The regulatory approval process is rigorous and time-consuming, but it is a necessary step for bringing new therapies to patients.
What Opportunities Does BMEA Have?
- Positive clinical trial data for BMF-219.
- Expansion of pipeline with new drug candidates.
- Strategic partnerships with larger pharmaceutical companies.
- Advancements in genomic research and personalized medicine.
What Threats Does BMEA Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Changes in the healthcare landscape.
What Are BMEA's Competitive Advantages?
- Proprietary covalent drug discovery platform.
- Strong intellectual property protection for its drug candidates.
- Expertise in developing covalent small molecule drugs.
What Does BMEA Do?
Biomea Fusion, Inc., founded in 2017 and headquartered in Redwood City, California, is a biopharmaceutical company dedicated to creating innovative treatments for genetically defined cancers and metabolic diseases. The company's core strategy revolves around developing covalent small molecule drugs, which form a strong, lasting bond with their target proteins, potentially leading to more effective and durable therapeutic outcomes. Their lead product candidate, BMF-219, is an orally bioavailable, potent, and selective covalent inhibitor of menin. Menin is a transcriptional regulator involved in oncogenic signaling in various cancers. BMF-219 is currently being evaluated in clinical trials for safety and efficacy in specific cancer subtypes. Biomea Fusion is focused on advancing BMF-219 through clinical development and expanding its pipeline with additional covalent small molecule drug candidates targeting other genetically defined diseases. The company aims to address unmet medical needs by developing therapies that offer improved outcomes for patients with limited treatment options.
What Products and Services Does BMEA Offer?
- Discovers and develops covalent small molecule drugs.
- Focuses on treatments for genetically defined cancers.
- Develops treatments for metabolic diseases.
- Their lead product candidate is BMF-219.
- BMF-219 is an orally bioavailable inhibitor of menin.
- Menin is a transcriptional regulator in oncogenic signaling.
How Does BMEA Make Money?
- Develops and patents novel covalent small molecule drugs.
- Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
- Generates revenue through milestone payments and royalties on partnered drugs.
What Industry Does BMEA Operate In?
Biomea Fusion operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop new treatments for unmet medical needs. Biomea Fusion's focus on covalent small molecule drugs and genetically defined diseases positions it within a niche segment of the market. The company faces competition from both established pharmaceutical companies and other emerging biotechnology firms developing therapies for similar indications. The overall biotechnology market is projected to continue growing, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in genomic research and drug discovery technologies.
Who Are BMEA's Key Customers?
- Patients with genetically defined cancers.
- Patients with metabolic diseases.
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
Key Financial Metrics
Return on assets is -96.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -83.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -54.8%, the inverse of the P/E and a quick read on earnings relative to price.
Biomea Fusion, Inc. (BMEA) Valuation Context
Valued at $82.40M, BMEA is classified as a micro-cap stock. Relative to its peer group, BMEA's quantitative score of 26/100 is below the peer average of 76/100.
Company Profile
Biomea Fusion, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Michael J. Hitchcock. BMEA has traded publicly since 2021.
F-Score 1/9Financial Health
Biomea Fusion, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.50 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Biomea Fusion, Inc. revenue of about $3.0M for fiscal 2026, with EPS near $-0.87. The estimate reflects 6 contributing analysts.
BMEA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in its value.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative approach to cancer treatments.
- Recent partnerships announced in the biotech space have boosted optimism about potential breakthroughs and market positioning.
- The company's promising clinical trial results have generated excitement among investors and analysts, enhancing its reputation in the industry.
Bear Case
- Concerns about regulatory hurdles remain, as navigating the FDA approval process can be lengthy and challenging for biotech firms.
- Market volatility has led to a cautious approach among investors, with some questioning the sustainability of recent gains.
- Bearish sentiment in the community has emerged, driven by skepticism about the scalability of Biomea's technologies and their commercial viability.
- Increased competition in the biotech sector could pose a threat, as rivals develop similar therapies that may overshadow Biomea's offerings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
BMEA Latest News
No recent news available for BMEA.
BMEA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMEA.
Price Targets
Wall Street price target analysis for BMEA.
BMEA MoonshotScore
What does this score mean?
The MoonshotScore rates BMEA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Biomea Fusion, Inc. Analysis
Leadership: Michael J. Hitchcock
CEO
Michael J. Hitchcock serves as the CEO of Biomea Fusion, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at various biotechnology companies, contributing to the advancement of novel therapies. Hitchcock's expertise spans areas such as oncology, metabolic diseases, and immunology. He has a strong track record of building and managing successful teams, driving innovation, and securing funding for research and development programs. His leadership is instrumental in guiding Biomea Fusion's strategic direction and advancing its pipeline of covalent small molecule drugs.
Track Record: Under Michael J. Hitchcock's leadership, Biomea Fusion has made significant progress in advancing its lead product candidate, BMF-219, through clinical trials. He has overseen the expansion of the company's pipeline and the establishment of strategic partnerships. Hitchcock has also been instrumental in securing funding to support the company's research and development efforts. His focus on innovation and execution has positioned Biomea Fusion as a promising player in the biotechnology industry.
Biomea Fusion, Inc. Healthcare Stock: Key Questions Answered
What does Biomea Fusion, Inc. do?
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery and development of covalent small molecule drugs for the treatment of genetically defined cancers and metabolic diseases. Their primary focus is on developing therapies that target specific genetic mutations or pathways involved in these diseases. The company's lead product candidate, BMF-219, is an orally bioavailable inhibitor of menin, a transcriptional regulator implicated in oncogenic signaling. Biomea Fusion aims to address unmet medical needs by creating innovative treatments that offer improved outcomes for patients with limited therapeutic options.
What do analysts say about BMEA stock?
Analyst coverage of Biomea Fusion, Inc. (BMEA) is still emerging, reflecting the company's early stage of development. Current analyst sentiment is cautiously optimistic, with a focus on the potential of BMF-219 and the company's innovative approach to covalent drug discovery. Key valuation metrics are influenced by the inherent risks associated with clinical-stage biotechnology companies. Growth considerations center on the successful advancement of BMF-219 through clinical trials and the expansion of the company's pipeline. Analyst ratings and price targets are subject to change based on clinical data readouts, regulatory developments, and overall market conditions.
What are the main risks for BMEA?
The main risks for Biomea Fusion, Inc. include the inherent uncertainties associated with drug development, such as the potential for clinical trial failures and regulatory hurdles. As a clinical-stage company, Biomea Fusion is heavily reliant on the success of its lead product candidate, BMF-219. Competition from established pharmaceutical companies and other biotechnology firms also poses a risk. Additionally, changes in the healthcare landscape, such as shifts in reimbursement policies or the emergence of new treatment modalities, could impact the company's prospects. Securing adequate funding to support ongoing research and development activities is also a critical risk factor.
What are the key factors to evaluate for BMEA?
Biomea Fusion, Inc. (BMEA) holds an AI score of 26/100 (low). Not financial advice.
How frequently does BMEA data refresh on this page?
BMEA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BMEA's recent stock price performance?
Biomea Fusion, Inc. (BMEA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative covalent drug discovery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BMEA overvalued or undervalued right now?
Valuing Biomea Fusion, Inc. (BMEA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BMEA?
Before investing in Biomea Fusion, Inc. (BMEA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.